PLB1004
Phase 3Small molecule
PLB1004 is one of 95 small molecule programs targeting Locally Advanced or Metastatic NSCLC. It is currently in Phase 3.
5
Indications
8
Total Trials
7
Active Trials
94
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaPhase 3
Ensacove
XXcovery Holdings, Inc.
Phase 3
Dato-Dxd
AstraZenecaPhase 3
PLB1004
AAvistone Biotechnology Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer3 trials
Locally Advanced or Metastatic NSCLC2 trials
Efficacy and Safety1 trial
EGFR Mutation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PLB1004. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAvistone Biotechnology Co., Ltd.